Fresenius raises 2026 earnings outlook following Q3 growth
Healthcare group Fresenius increased its full-year earnings forecast after reporting a 14% rise in core earnings per share for the third quarter of 2026.
Fresenius reported third-quarter revenue of €5.8 billion, marking a 5% organic growth rate. The company’s EBIT rose by 10% in constant currency to €638 million, while core earnings per share (EPS) increased by 14% to €0.72. These results prompted management to lift its 2026 core EPS guidance to the upper half of its existing 10%–15% growth target.
Growth was primarily driven by the Fresenius Kabi division, where the biopharma unit recorded a 29% expansion. The Helios hospital segment also contributed with 5% organic growth and improved margins. CEO Michael Sen noted that the performance reflects the successful execution of the company's internal restructuring and cost-reduction initiatives.
Separately, Fresenius announced a strategic development agreement with WuXi Biologics. The partnership grants exclusive access to up to 37 potential biosimilar candidates, positioning the company to significantly expand its drug portfolio over the next decade.
The company achieved a 7% return on invested capital, representing a ten-year high. Fresenius remains focused on debt reduction and operational efficiency to support its long-term growth objectives.